Cadila Healthcare announces settlement of patent litigation for generic Revlimid in US

Cadila Healthcare and its subsidiary Zydus Pharmaceuticals (USA) Inc. have reached an agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb relating to patents for Revlimid (lenalidomide).

As part of the settlement, the parties will file consent judgments with the United States District Court for the District of New Jersey that enjoin Zydus Cadila from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement.

Cadila Healthcare reported 40.6% rise in consolidated net profit to Rs 512.50 crore on a 6.2% rise in net sales to Rs 3,753.70 crore in Q3 FY21 over Q3 FY20.

Shares of Cadila Healthcare was down 0.02% to Rs 430.95 on BSE. Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News